Battling the Odds in RCC: Interview With Brian Rini, MD
An interview with Brian Rini, MD, whose research has focused on RCC, prostate, and other genitourinary cancers, as well as on antiangiogenic therapy and immunotherapy.
Study Supports Combining c-MET Targeted Therapies With Angiogenesis Inhibitors
Agents that target the c-MET pathway may prove to have significant benefit when combined with inhibitors of angiogenesis.
Brivanib Plus Cetuximab Delivers Mixed Results in Colorectal Study
Adding brivanib alaninate to cetuximab had no survival advantage over cetuximab alone in patients with KRAS wild-type chemorefractory metastatic colorectal cancer.
Research Backs Anti-EGFR Therapy in mCRC With Wild-Type KRAS
New research on predictive and prognostic biomarkers for therapy targeting EGFR strongly suggests that panitumumab should be reserved for mCRC tumors with wild-type KRAS.
Optical Biomarkers Distinguish Risk Levels in Barrett's Esophagus
Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.
Dual Inhibitors Explored in Triple-Negative Tumors
The use of advanced gene analysis techniques
in a small group of women with triple-negative
metastatic breast cancer has revealed
activity in two pathways found in most patients with this subtype.
Support for LDCT Screenings of Heavy Smokers Is Growing
The concept of screening people at high risk for developing lung cancer with low-dose computed tomography continues to gain support in the oncology community.
Examining Crizotinib's Potential Uses
The development of crizotinib has helped crystallize a relatively rare molecular subset of NSCLC and holds the potential for wider use in treating patients with the disease.
Database Analysis Finds IMRT More Effective Than CRT and Proton Beam in Prostate Cancer
IMRT was superior to CRT in reducing recurrence and significant side effects in men with localized prostate cancer, according to a comparative effectiveness study based on the SEER-Medicare database.
Examining the HER2 Testing Puzzle: Fresh Research Explores Nagging Questions
HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.
MET Receptor Pathway: A Bounty of Targeted Options Explored
The MET signaling network has emerged as an important target for cancer therapy, with a particularly significant role in controlling the cancer hallmarks of metastasis and angiogenesis.
Five Questions for Jill M. Siegfried, PhD
Jill M. Siegfried, PhD, is an investigator into the role of growth factors and hormones in the development and growth of lung cancer.
Analyzing Disease Flares: Impact of Discontinuing Targeted Therapy Unclear
It is always difficult to distinguish what may legitimately be considered disease flare from the more likely scenario of the events simply representing the natural history of the malignancy.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.